Eli Lilly and Co

High Adderall doses linked to fivefold increased risk of first-time psychosis or mania, especially above 40 mg.

Zepbound, an injectable weight-loss drug, shows better efficacy in women, with up to 25% weight loss compared to 19% in men. Tirzepatide, the active ingredient, consistently reduced weight in both sexes, but more research is needed to understand why women experience greater weight reduction.

Immunovant to launch late-stage trial for Graves' disease, targeting FcRn to block harmful IgG autoantibodies, aiming to improve control of hyperthyroidism and thyroid eye disease.

ALX Oncology Holdings Inc. develops Evorpacept [ALX148], a first-in-class CD47 inhibitor with an inactive Fc domain reducing side effects. ASPEN-06 Phase 2 trials combining Evorpacept with trastuzumab, ramucirumab, and paclitaxel (TRP) showed favorable results in HER2-positive gastric and gastroesophageal junction (GEJ) cancer. Evorpacept has FDA Fast Track designations for several indications, making the shares potentially bullish.

Novo Nordisk's Saxenda (liraglutide) showed a 5.8% mean BMI reduction in children aged 6-12 with obesity in a Phase III trial, compared to 1.6% in the placebo group. The trial data supports Novo Nordisk's plan to expand Saxenda's label to include younger obese children.

Innovent Biologics announces Phase 3 results for mazdutide, a GLP-1R/GCGR dual agonist, showing superiority to dulaglutide in glycemic control and weight loss in Chinese T2D patients. Mazdutide also improves cardiometabolic risk factors and has a favorable safety profile. Two NDAs for mazdutide are under review in China.

The weight-loss treatment market is expected to see 16 new drugs by 2029, expanding the market to $200 billion by 2031, driven by interest sparked by Novo Nordisk and Eli Lilly. Amgen and Pfizer are among companies testing their drug candidates, which could lower prices amid criticism over high costs.

Abbott announces US availability of Lingo CGM for non-insulin users, priced at $49 for 14-day biosensor. Embecta receives FDA clearance for tubeless patch pump with 300-unit insulin reservoir, designed for adults with diabetes, aiming to meet 64% of T2D needs for three-day wear.

Natureferm, owned by Waukon natives Jim and Jody Zahn, opened an R&D center at 17 1st Street NW in May, focusing on developing a life-saving drug for Wilson disease in partnership with Iowa State University, the University of Michigan, and a German Research Institute. The company provides biotechnology R&D services, aiming to improve existing products or make them more affordable.